ESTA vs. TMDX, NVST, SLNO, LIVN, WRBY, EYE, INSP, PRCT, LMAT, and AORT
Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include TransMedics Group (TMDX), Envista (NVST), Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), National Vision (EYE), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), and Artivion (AORT). These companies are all part of the "medical equipment" industry.
Establishment Labs vs. Its Competitors
Establishment Labs (NASDAQ:ESTA) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by company insiders. Comparatively, 7.0% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
TransMedics Group has a net margin of 13.49% compared to Establishment Labs' net margin of -49.89%. TransMedics Group's return on equity of 28.02% beat Establishment Labs' return on equity.
Establishment Labs has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.
In the previous week, TransMedics Group had 9 more articles in the media than Establishment Labs. MarketBeat recorded 18 mentions for TransMedics Group and 9 mentions for Establishment Labs. TransMedics Group's average media sentiment score of 0.54 beat Establishment Labs' score of 0.25 indicating that TransMedics Group is being referred to more favorably in the news media.
TransMedics Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Establishment Labs currently has a consensus price target of $56.50, suggesting a potential upside of 25.74%. TransMedics Group has a consensus price target of $127.18, suggesting a potential upside of 12.19%. Given Establishment Labs' stronger consensus rating and higher probable upside, equities research analysts plainly believe Establishment Labs is more favorable than TransMedics Group.
Summary
TransMedics Group beats Establishment Labs on 13 of the 16 factors compared between the two stocks.
Get Establishment Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Establishment Labs Competitors List
Related Companies and Tools
This page (NASDAQ:ESTA) was last updated on 10/14/2025 by MarketBeat.com Staff
